Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Authorization Study to Monitor Efficacy, Effectiveness, and Safety of Maribavir (LIVTENCITY) in Adult Patients With Post-transplant Cytomegalovirus (CMV) Infection in Argentina

Next Previous
Trial Profile

Post Authorization Study to Monitor Efficacy, Effectiveness, and Safety of Maribavir (LIVTENCITY) in Adult Patients With Post-transplant Cytomegalovirus (CMV) Infection in Argentina

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maribavir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors Takeda

Most Recent Events

  • 15 Oct 2024 Status changed from not yet recruiting to recruiting.
  • 29 Aug 2024 Planned initiation date changed from 1 Aug 2024 to 10 Sep 2024.
  • 22 Jul 2024 Planned initiation date changed from 1 Jun 2024 to 1 Aug 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top